Regulatory And Policy News, In Brief
Executive Summary
Endo's Advisory Committee Cancelled
You may also be interested in...
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Advisory Panel For Bristol's Yervoy Is Called Off, Which May Bode Well
After extending the review, FDA says it no longer needs ODAC's advice on the second-line melanoma treatment, which looks like a good sign for approval.
Portola's Heart Bypass Drug Gets Closed Advisory Committee Session
FDA's Cardiovascular and Renal Drugs Advisory Committee will discuss Portola Pharmaceuticals' thromboxane receptor antagonist PRT061103, intended to prevent cardiovascular problems in patients who have developed intolerance to aspirin.